Abstract
We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-α failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined after treatment for 3 months. We identified a low neutrophil count and poor cytogenetic response (
Original language | English |
---|---|
Pages (from-to) | 1448-1453 |
Number of pages | 6 |
Journal | Leukemia |
Volume | 17 |
Issue number | 8 |
DOIs | |
Publication status | Published - Aug 1 2003 |
Keywords
- Chronic myeloid leukaemia
- Cytogenetic response
- Imatinib mesylate
- Neutropenia
- Prognostic factors
ASJC Scopus subject areas
- Hematology
- Cancer Research